WP
LXEO icon

Woodline Partners’s Lexeo Therapeutics LXEO Stock Holding History

Woodline Partners’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.8M Sell
2,750,532
-447,228
-14% -$3.17M 0.06% 392
2025
Q4 		$31.8M Buy
3,197,760
+625,598
+24% +$5.71M 0.12% 212
2025
Q3 		$17.1M Hold
2,572,162
– – 0.08% 319
2025
Q2 		$10.3M Buy
2,572,162
+1,735,148
+207% +$5.71M 0.05% 424
2025
Q1 		$2.9M Sell
837,014
-21,677
-3% -$96K 0.02% 610
2024
Q4 		$5.65M Buy
858,691
+6,730
+0.8% +$53K 0.04% 462
2024
Q3 		$7.7M Buy
851,961
+27,887
+3% +$333K 0.07% 336
2024
Q2 		$13.2M Buy
824,074
+812,023
+6,738% +$11.8M 0.13% 219
2024
Q1 		$189K Buy
+12,051
New +$188K ﹤0.01% 517

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return